From the Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.
Cancer J. 2021;27(1):67-75. doi: 10.1097/PPO.0000000000000499.
Poly(ADP-ribose) polymerase (PARP) is involved in single-strand DNA break base excision repair. PARP inhibition causes synthetic lethality in breast cancers associated with germline BRCA1 and BRCA2 mutations and is routinely used in clinical practice for metastatic breast cancer. Breast cancers with homologous recombination deficiency or BRCAness, most commonly triple-negative breast cancers, may also benefit. Currently, PARP inhibitor use for triple-negative breast cancer with wild-type BRCA does not have definitive efficacy; however, this is an area of active research. Further clinical and translational data may identify additional patient populations that will benefit from PARP inhibitor therapy.
聚（ADP-核糖）聚合酶（PARP）参与单链 DNA 断裂碱基切除修复。PARP 抑制导致与种系 BRCA1 和 BRCA2 突变相关的乳腺癌发生合成致死，并且在临床上常规用于转移性乳腺癌。同源重组缺陷或 BRCA 样的乳腺癌，最常见的三阴性乳腺癌，也可能受益。目前，PARP 抑制剂在野生型 BRCA 的三阴性乳腺癌中的应用尚没有明确的疗效；但是，这是一个活跃的研究领域。进一步的临床和转化数据可能会确定其他将受益于 PARP 抑制剂治疗的患者人群。
